Ainos, Inc. (NASDAQ: AIMD, AIMDW) ("Ainos", or the "Company"), a diversified medtech company focused on the development of novel point-of-care testing, low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced the launch of two new VELDONA® Pet cytoprotein supplement products.
Ainos Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20M Revenue Target albuquerqueexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from albuquerqueexpress.com Daily Mail and Mail on Sunday newspapers.
Verrica Pharmaceuticals (NASDAQ:VRCA – Get Rating) and Ainos (OTCMKTS:AIMD – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation. Institutional & Insider Ownership 24.9% of Verrica Pharmaceuticals shares are […]
Ainos Launches New VELDONA Pet Lohas and Soothing Health Supplements, Catalyzing Its Drive to $20M Sales Target theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.
New products support pets' emotional health and allergic responses, hit market in Taiwan following successful launch of VELDONA® PetExpanding VELDONA® Pet product line builds growth momentum toward US$20M